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Abstract
Neuroprotectin D1 (NPD1) is a stereoselective mediator derived from the omega-3 essential fatty acid docosahexaenoic acid
(DHA) with potent inflammatory resolving and neuroprotective bioactivity. NPD1 reduces Ab42 peptide release from aging
human brain cells and is severely depleted in Alzheimer’s disease (AD) brain. Here we further characterize the mechanism of
NPD1’s neurogenic actions using 3xTg-AD mouse models and human neuronal-glial (HNG) cells in primary culture, either
challenged with Ab42 oligomeric peptide, or transfected with beta amyloid precursor protein (bAPP)sw (Swedish double
mutation APP695sw, K595N-M596L). We also show that NPD1 downregulates Ab42-triggered expression of the pro-
inflammatory enzyme cyclooxygenase-2 (COX-2) and of B-94 (a TNF-a-inducible pro-inflammatory element) and apoptosis
in HNG cells. Moreover, NPD1 suppresses Ab42 peptide shedding by down-regulating b-secretase-1 (BACE1) while
activating the a-secretase ADAM10 and up-regulating sAPPa, thus shifting the cleavage of bAPP holoenzyme from an
amyloidogenic into the non-amyloidogenic pathway. Use of the thiazolidinedione peroxisome proliferator-activated
receptor gamma (PPARc) agonist rosiglitazone, the irreversible PPARc antagonist GW9662, and overexpressing PPARc
suggests that the NPD1-mediated down-regulation of BACE1 and Ab42 peptide release is PPARc-dependent. In conclusion,
NPD1 bioactivity potently down regulates inflammatory signaling, amyloidogenic APP cleavage and apoptosis,
underscoring the potential of this lipid mediator to rescue human brain cells in early stages of neurodegenerations.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease
characterized by progressive cognitive impairment and, at the
cellular level, by synaptic damage, intracellular neurofibrillary
tangles and beta-amyloid precursor protein (bAPP) processing
dysfunction that leads to overabundance of the 42 amino acid
amyloid-beta (Ab42) peptide. Ab42 promotes neuroinflammation,
synaptic toxicity, and apoptosis, and it transitions extracellularly
from an oligomer to an aggregate that, in turn, become a major
component of senile plaques [1–6]. Ab42 peptides are generated
from bAPP via tandem cleavage by beta- and gamma- (b- and c-)
secretases; alternatively an alpha-secretase distintegrin and me-
talloproteinase 10 (ADAM10) cleaves bAPP to yield a soluble form
of bAPP, sAPPa, via the non-amyloidogenic or neurotrophic
pathway.
Docosahexaenoic acid (DHA; C22:6), an omega-3 essential
fatty acid family member, is enriched in central nervous system
(CNS), synaptic and other cellular membranes as an acyl chain of
membrane phospholipids. DHA is involved in the building and
function of the CNS, as well as synaptogenesis, cognition,
neuroprotection, synaptic function and vision [7–10]. Current
clinical trials favor a role for DHA in slowing cognitive decline in
elderly individuals without dementia but not for the prevention or
treatment of dementia, including AD [11,12]. Deficiencies in
DHA biosynthesis by the liver correlate with cognitive impair-
ment in AD patients [13], supporting the significance of the liver
supply of DHA to the CNS in neurodegenerative diseases
[13,14]. In AD transgenic mice dietary DHA restores cerebral
blood volume, reduces Ab deposition, and ameliorates Ab
pathology [15,16].
The recent identification of the DHA-derived stereoselective
mediator neuroprotectin D1 (NPD1; 10R,17S-dihydroxy-docosa-
4Z,7Z,11E,15E,19Z hexaenoic acid) provides a specific mecha-
nism to understand DHA-mediated modulation of neuroinflam-
mation and neuroprotection. NPD1 elicits neuroprotective activity
in brain ischemia-reperfusion and in oxidative-stressed retinal cells
[17–19]. DNA microarray profiling suggests a down-regulation of
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the Bcl-2 gene family [9]. NPD1 further influences bAPP
processing and decreases Ab42 release [9], and its precursor
DHA elicits an Ab42-lowering effect both in vitro and in vivo
[8,20,21]. In addition, free radical-mediated DHA peroxidation
products accumulate during ischemia and neurodegeneration.
These oxidation products in turn may form protein adducts and
other cytotoxic molecules that promote further free radical injury
[22–24].
The ligand-activated transcription factor peroxisome prolifera-
tor-activated receptor c (PPARc) regulates lipoprotein metabo-
lism, adipogenesis and insulin sensitivity, and it has been
implicated in AD [25–30]. PPARc activation underlies some of
DHA’s anti-inflammatory actions [31–34]. Moreover, PPARc is a
potential NPD1 target since it has a fatty acid binding pocket for
polyunsaturated fatty acids [31] and their derivatives, including
DHA [35].
In the present study, we assessed DHA and NPD1 abundance in
control and aged 3xTg-AD mouse hippocampus and used aging
human neuronal-glial (HNG) primary cells to characterize NPD1
bioactivity on: neuroinflammatory events and apoptosis; to test the
mechanism of NPD1-mediated regulation of Ab42 secretion; and
to assess the significance of PPARc in the homeostatic bioactivity
of NPD1. Here we provide evidence that, besides protecting
against Ab42-induced neurotoxicity via anti-inflammatory and
anti-apoptotic bioactivity, NPD1 down-regulates the amyloido-
genic processing of bAPP, thus reducing Ab42 production.
Moreover, NPD1 anti-amyloidogenic action through selective
targeting of both the a- and b-secretase-mediated processing of
bAPP and anti-amyloidogenic action are exerted through PPARc
receptor activation.
Materials and Methods
Studies and procedures were performed according to National
Institutes of Health and Canadian Council on Animal guidelines,
and animal protocols were approved by the Institutional Animal
Care and Use Committee at the Louisiana State University Health
Sciences Center, New Orleans (IACUC #2705, IBC# 08126 and
082303), and by the Laval University Animal Ethics Committee
(approval ID =07–113 and 07–061).
Reagents and Antibodies
The following reagents and antibodies were obtained commer-
cially and used without further purification: Ab42 peptides
(American Peptide, Sunnyvale, CA); antibodies for COX-2,
APP-NT, APP-CT and b-actin (Sigma, St Louis, MS); antibodies
for B94, ADAM9, ADAM10, BACE1 and PS1 (Santa Cruz
Biotechnology, Santa Cruz, CA); antibodies for sAPPa and
sAPPbsw (American Research Products, Belmont, MA); IRDyeTM
700 or 800 infrared dye-labeled secondary antibodies (Rockland
Immunochemicals, Gilbertsville, PA); FITC fluorescein conjugat-
ed secondary antibody (BD Biosciences, San Jose, CA); Cy3
fluorescein conjugated secondary antibody (GE Healthcare,
Piscataway, NJ). Additional BACE1 antibodies Ab2077 (Abcam,
Cambridge MA); sc-73729 and sc-33711 (Santa Cruz); PA1-757
(Affinity Bioreagents, Rockford, IL) and 61-3E7 (MAB5308,
Millipore, Billerica, MA) were used to analyze BACE1 abundance;
the identity of BACE1 was also confirmed via C-terminal micro-
sequencing (data not shown). DHA was obtained from (Cayman
Chemical, Ann Arbor, MI) and stereochemically pure NPD1 was
prepared via total organic synthesis and quantified according to
reported chemical and physical procedures using molecular
biology grade ethanol as vehicle (concentration 0.1 mg/ml
,0.3 mM) [36,37].
3xTg-AD Animals
3xTg-AD mice, harboring the PS1 (M146V), APP (Swe) and tau
(P301L) human transgenes were reared according to established
protocols and received control diets (Teklad 2018, rodent diet;
Harlan Teklad, Inianapolis IN) [38,39]. Non-transgenic mice used
here were littermates from the original PS1-knockin mice and are
on the same background as 3xTg-AD mice (C57BL6/129SvJ)
[39]. Animals (N=5 to 6 per group) were sacrificed at 4 and 12–
13 months and the frontal lobe, rostro-temporal lobe and
hippocampus were isolated and analyzed for DHA and NPD1
using LC-PDA-ESI-MS-MS as previously reported [9,17,18,37]
(Figure 1).
Human neuronal-glial (HNG) Cell Culture
We used stressed primary human neuronal-glial co-culture
(HNG) as a cellular model to address NPD1-mediated signaling
and mechanistic questions relevant to AD [9,27,40,41]. In brief,
human neural progenitor cells (Lonza, Allendale, NJ) were
initially plated as free-floating aggregates (neurospheres) in a
75 cm
2 uncoated plastic flask in neural progenitor basal medium
(NPBM) supplemented with human recombinant basic fibroblast
growth factor (hbFGF), human recombinant epidermal growth
factor (hEGF) and human leukemia inhibitory factor (hLIF).
Differentiation into HNG cells was induced by plating neuro-
spheres onto 6-well plates pre-coated with poly-L-ornithine and
cultured in neurobasal medium supplemented with 16B27
(Invitrogen, Carlsbad, CA) and 1% of FBS. Cells were
subsequently cultured for 1 week until 80% confluence at 37uC
in a humidified 5% CO2 atmosphere incubator; 24 hours after
plating HNG cells then strongly adhere to the plate bottom
[9,27].
Figure 1. DHA and NPD1 analysis in 3xTg-AD hippocampus.
DHA and NPD1 levels were analyzed using liquid chromatography-
photodiode array-electrospray ionization-tandem mass spectrometry
(LC-PDA-ESI-MS-MS) [9]. 3xTg-AD mouse brain hippocampus was
sampled at 4 and 12–13 months and were compared to age-matched
controls. DHA levels were reduced to 0.61-fold of control between 12–
13 and 4 month old 3xTg AD mice (A); similarly NPD1 levels were
reduced to 0.22-fold of control in 12–13 month old 3xTg-AD mice
compared to 4 month 3xTg-AD mice (B). *p,0.05; ** p,0.01 (ANOVA).
doi:10.1371/journal.pone.0015816.g001
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Cells
Plasmid containing APP695 cDNA bearing the Swedish
mutation APPsw (Swedish double mutation APP695sw, K595N,
M596L) was a generous gift from Dr. T Golde of the Mayo Clinic
(Jacksonville, FL). cDNA clones of full length hBACE1 genes were
from Open Biosystem (Huntsville, AL). HNG cells were plated in 6-
well plates at 80% confluence and transiently transfected using
Fugene HD transfection reagent (Roche Applied Science, India-
napolis, IN)with2 mg perwell ofhAPP695swplasmid DNAaloneor
together with pEGFP (green fluorescent protein; BD Biosciences-
Clontech), hPPARc, or hBACE1 at a DNA (mg):reagent (ml) ratio of
1:3. After 24 h, cells were typically incubated with 0, 50, 100 or
500 nM NPD1 or vehicle for 48 h before assay.
Small Interfering RNA-mediated Gene Silencing
HNG cells were transfected with predesigned siRNA (Santa
Cruz Biotechnology) to knock down human ADAM9 or ADAM10
mRNA. HNG cells over-expressing bAPPsw were transfected with
a total of 60 pmol of ADAM9, ADAM10 or control siRNA using
Lipofectamine 2000 transfection reagent (Invitrogen) and cultured
for 24 h. The medium was replaced with a fresh one containing
500 nM of NPD1 and cells were cultured for another 48 h before
assay.
Ab42 Oligomer Preparation
Ab42 peptides were initially solubilized in hexafluoroisopropa-
nol (HFIP) (Sigma), aliquoted, and stored at 220uC as an HFIP
film [42]. After evaporating HFIP, aliquoted peptide was re-
suspended with DMSO to 5 mM and diluted with phenol red free
F12 media (Invitrogen) to a concentration of 100 mM. Peptide for
the oligomer preparation was incubated at 4uC for 24 h prior to
use [42]. The oligomeric status of Ab was verified by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE;
Figure S1).
Immunocytochemistry and Imaging Analysis
HNG cells cultured on 8-well chamber slides (BD Biosciences,
San Jose, CA) were fixed with 4% paraformaldehyde, then
permeabilized and blocked with 0.125% Triton X-100 (Sigma)
and 2% normal goat serum (GE Healthcare) in PBS at room
temperature (RT) for 1 h. Cells were incubated overnight at 4uC
with antibodies for b-tubulin III, GFAP, COX-2, B94 or APP-NT.
Cells were washed 3 times with PBS and incubated for 3 h at RT
with secondary antibodies conjugated with Cy3 or FITC
fluorescein. After washing and drying, slides were applied with
mounting medium (Vector Laboratories, Burlingame, CA) and
observed under Zeiss Axioplan Inverted Deconvolution Fluores-
cent Microscope (Carl Zeiss, Oberkochen, Germany). Positively-
stained cells were quantified using the manual counter function of
the NIH ImageJ software.
Mediator lipidomic analysis
Lipids were extracted by homogenization of cells or tissues in
chloroform/methanol and stored under nitrogen at 280uC
[17,18,36]. For quantification, lipid extracts were supplemented
with deuterated labeled internal standards, purified by solid-phase
extraction, and loaded onto a Biobasic-AX column (Thermo-
Hypersil-Keystone; 100 mm 62.1 mm; 5-mm particle sizes) run
with a 45-min gradient protocol, starting with solvent solution A
(40:60:0:01 methanol:water:acetic acid, pH 4.5; 300 ml/min); the
gradient typically reached 100% solvent B (99.99:0.01 methano-
l:acetic acid) in 30 min, and was then run isocratically for 5 min. A
TSQ Quantum (Thermo-Finnigan) triple quadrupole mass
spectrometer and electrospray ionization was used with spray
voltage of 3 kV and N2 sheath gas (35 cm
3/min, 350uC). Parent
ions were detected on full-scan mode on the Q1 quadrupole.
Quantitative analysis was performed by selective reaction
monitoring. The Q2 collision gas was argon at 1.5 mTorr, and
daughter ions were detected on Q3. Selected parent/daughter ion
pairs for NPD1 and unesterified DHA were typically 359/153 m/z
and 327/283 m/z, respectively. Calibration curves for NPD1 and
DHA (Cayman Chemical) were acquired; NPD1 was generated
via biogenic synthesis using soybean lipoxygenase and DHA,
purified by HPLC, and characterized by LC-PDA-ESI-MS-MS
according to reported biophysical criteria [9,17].
MTT cell viability assay, Hoechst staining, TUNEL assay
and caspase-3 activity assay
Cell viability was measured by 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) reduction assay (Sigma).
HNG cells were incubated with 5 mMo fA b42 in the absence or
presence of 50 nM of NPD1 for 48 h. MTT was added to a final
concentration of 0.5 mg/ml and incubated for 2 h. Medium was
then removed and equal volumes of isopropanol were added to
dissolve the resulting formazan crystals. Absorbance was spectro-
photometrically measured with a SpectraMax Microplate Reader
(Molecular Devices, Sunnyvale, CA) at 570 nm. HNG cells were
further incubated with 2 mM Hoechst 33258 (Invitrogen) for
45 min at 37uC before imaging. Cells were then viewed by using a
Nikon DIAPHOT 200 microscope under UV fluorescence.
Images were recorded by a Hamamatsu Color Chilled 3CCD
camera and PHOTOSHOP 7.0 software. Positively stained cells
were counted manually using ImageJ software. The apoptotic
nuclei containing free 39-OH termini were detected using
DeadEnd Fluorometric TUNEL Kit (Promega, Madison, WI).
Samples were analyzed under a Zeiss Deconvolution Microscope.
Caspase-3 activity from cell lysates was detected using Caspase 3
Colorimetric Assay Kit (Sigma). The absorbance was measured at
405 nm using a SpectraMax Microplate Reader.
Total RNA Extraction and RT-PCR
HNG cells were lysed and total RNA was extracted with TRIzol
(Invitrogen). RNA quality and quantity were analyzed by using a
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). 28S/
18S ratio for each RNA sample was typically greater than 1.8. For
reverse transcription, a Superscript III First-Strand SuperMix
(Invitrogen) was used. 1 mg of total RNA was used as a template to
react with 10 mlo f2 6RT Reaction Mix and 2 ml RT Enzyme Mix.
Final total volume was 20 ml. Samples were incubated at 25uC for
10 min and then 50uC for 30 min. Reactions were stopped by
heating to 85uC for 5 min, and RT product was amplified with
Phusion High Fidelity DNA Polymerase in a GeneAmp PCR
System 9700 (Applied Biosystems, Foster City, CA). The primers
used in these experiments (Integrated DNA Technologies, Coral-
ville, IA) and their sequences are as follows: 59-TTTGATGAT-
GGCGTACTTGG-39,5 9-AGTTTGTCCCCAGATGTTGC-39
for ADAM10; 59-TACAATGCTGACTATGGCTAC-39,5 9-CT-
GATGCGTGAAGTGCTG-39 for COX-2; 59-CAAAGTAGAC-
CTGCCCAGAC-39,5 9-GACCTCTCTCTAATCAGCCC-39 for
TNF-a;5 9-TGAGGACCTGAAG CCACTGTTCAA-39,5 9-TG-
CGCTTGACCTCACTGTTGGATA-39 for B94 and 59-AGA-
TGTGGATCA GCAAGCAGGAGT-39,5 9-GCAATCAAAGT-
CCTCGGCCACATT-39 for b-actin (internal control; Lukiw and
Pogue 2007; Lukiw et al., 2005). The PCR consisted of initial
incubation at 98uC for 45 s, denaturation at 98uC for 10 s,
annealing at 56uC for 30 s and extension at 72uC for 20 s, for 35
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further analyzed on 1.5% agarose gels; relative band intensity was
quantified using Quality One software (Invitrogen).
SDS-PAGE and Western Blotting
Conditioned media were collected from cultured HN cells after
various treatments and protease inhibitor cocktail (Sigma) was
added to 1% final concentration [9,27]. Cells were then washed
twice with ice-cold DPBS and lysed and harvested in RIPA buffer
(Sigma) supplemented with 2% protease inhibitor cocktail, then
centrifuged at 10,0006 g for 15 min at 4uC. Supernatants were
collected and quantified using Bio-Rad’s (Hercules, CA) DC
Protein Assay kit. 30 mg of cell lysate or 20 ml - of conditioned
media were electrophoresed on 4–15% Tris-HCl gradient gels at
100 V for 80 min or 10–20% Tris-Tricine gels for the detection of
CTFs at 50 mA for 120 min. Proteins were transferred to an
Immobilon FL PVDF membrane (Millipore, Billerica, MA) at 100
V for 60 min. Membranes were incubated with primary antibody
overnight at 4uC, followed by incubation with IRDye 800 or Alexa
680-conjugated secondary antibodies for 5 h at RT. After
repeated washing with Tris-buffered saline, the membrane was
then visualized by the Odyssey Infrared Imaging System (LI-
COR, Lincoln, NE).
Sandwich ELISA Analysis of TNFa and Ab42
Secreted TNF-a,A b42 and total Ab were detected using a
Human TNF ELISA Kit (BD Biosciences, San Jose, CA), a human
amyloid b 42 ELISA kit (Sigma) and a human amyloid b (1-x)
assay kit (American Research Products), respectively. After
reactions, the plates were immediately measured at 450 nm by a
SpectraMax Microplate Reader.
Human Preadipocyte Differentiation Assay
Human preadipocytes maintenance and differentiation proce-
dures were performed according to the manufacturer’s instructions
with modifications (Zen-Bio, Research Triangle Park, NC). Briefly,
upon the initiation of the differentiation assay, preadipocytes were
incubatedinadipocytemediumsupplementedwithIBMX(0.5 mM)
and NPD1, DHA or vehicle. A concentration range of 0.1–5 mMo f
each lipid was used. After 3-day incubation, the cell medium was
replacedwiththeadipocytemediumwithoutIBMX.Eightdaysafter
vehicle or lipid treatment, the media was removed and the cells were
fixed with formalin (7% formaldehyde in PBS). Cells were then
stained with Oil Red O (Sigma, Saint Louis, MS) and pictures were
taken with a Nikon Eclipse TS100 invertedmicroscope(Nikon USA,
Melville, NY). The Oil Red O-stained total lipid was then eluted
with 100% isopropanol and quantified by measuring OD value at
500 nm with a SpectraMax Microplate Reader.
Cell-based PPARc Transactivation Assay
The two plasmids used for the transactivation assay (PPARc-
GAL4 and MH100-tk-luc) were kindly provided by Dr. Ronald
Evans of Salk Institute (La Jolla, CA) [32]. Luciferase assay was
performed using Promega’s Luciferase Assay System. Light units
Figure 2. NPD1 promotes cell survival in Ab42 oligomer stressed-human HNG cells in primary culture. HNG cells were treated for 48 h
with 5 mMo fA b42 oligomer in the absence or presence of NPD1 (50 nM). (A) NPD1 promotes HNG cell survival in response to Ab42 neurotoxicity as
shown by MTT cell viability assay following reduction of the tetrazolium salt MTT (Sigma-Aldrich). Results, expressed as the percentage of cell survival,
are the means 6 SEM of three experiments performed in triplicate. Untreated cells were 100% viable. Panels (B-G) depict anti-apoptotic effect of
NPD1 by combining Hoechst 33258 staining, phase contrast microscopy, TUNEL assay and caspase-3 activity assay. (B) Upper panel illustrates the
appearance of Hoechst 33258 positive cells upon different treatments (206 magnification); (C) middle panel shows phase-contrast images of
corresponding HNG cells. (D) Number of Hoechst 33258-positive apoptotic nuclei per 100 of total cells (n=5). (E) TUNEL (green fluorescence) assay
and (DAPI) (blue) staining (206 magnification) of HNG cells. (F) Percentage of TUNEL-positive cellular nuclei in each treatment group (n=5). (G)
Caspase-3 activity of HNG cells after Ab42 peptide and NPD1 treatment; dashed horizontal line at 1.0 indicates control caspase-3 activity for ease of
comparison; (n=3). Data are expressed as means 6 SEM. *p,0.01 vs. control; **p,0.01 vs. Ab42 peptide.
doi:10.1371/journal.pone.0015816.g002
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in a Luminoskan Ascent microplate luminometer (Thermo Fisher
Scientific, Waltham, MA). Luciferase values were expressed as
relative light units and normalized to the level of b-galactosidase
activity. Changes in PPARc activity were expressed as ‘‘fold
induction’’ relative to the vehicle control values (Figure S2).
Figure 3. NPD1 down-regulates the expression of the pro-inflammatory genes COX-2, TNFa and B94, compared to b-actin levels in
the same sample, in response to Ab42 oligomer (5 mM); rescue by NPD1 (50 nM). (A) COX-2 and b-actin mRNA expression was detected by
RT-PCR followed by agarose gel electrophoresis. (B) Western blot detection of TNFa, B94 and b-actin expression in control or Ab42 peptide-stressed
HNG cells at 3, 6 and 12 h in the presence or absence of NPD1. (C) Immuno-fluorescent staining of COX-2 or B94 (red). Nuclei were visualized using
DAPI (blue) (206magnification). Quantitative analysis of COX-2 and B94 gene expression (n=3 to 5; see Figure 5).
doi:10.1371/journal.pone.0015816.g003
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All experiments were repeated at least three times using independent
culture preparations. Data are presented as mean 6 S.E. Quantitative
data were statistically analyzed by one-way analysis of variance
(ANOVA) followed by pair-wise comparisons using the Fisher’s least
significant difference test. A p,0.05 was considered significant.
Results
DHA and NPD1 deficits in 3xTg-AD mouse hippocampus
DHA and NPD1 levels were assayed in the hippocampus of
3xTg-AD mice, harboring the PS1 (M146V), APP (Swe) and tau
(P301L) human transgenes that model several human AD features
[38,39]. DHA and NPD1 levels were analyzed using LC-PDA-
ESI-MS-MS-based lipidomic analysis as previously described
(Figure 1) [9,18]. Both DHA and NPD1 showed age-related
changes in 4-month old versus 12–13 month old 3xTg-AD
animals. DHA concentration in the hippocampus was found to be
reduced 2-fold between 4-month old control versus 4-month
3xTg-AD animals, and 3-fold between 4 and 12-13 month old
control animals (Figure 1A). NPD1 in the hippocampus showed
dramatic reductions both in aging control animals; a 12-fold
reduction between 4 and 12–13 month controls and a 3-fold
reduction between 4 and 12–13 month 3xTg-AD mice
(Figure 1B).
NPD1 protects HNG cells from Ab42-induced apoptosis
Phase contrast and immunofluorescence of differentiated HNG
cells expressing the neuronal marker b-tubulin III and the
astrocyte marker glial fibrillary acidic protein (GFAP) revealed
neuronal-glial co-cultures containing about 50% neurons under
these conditions (Figure 2). NPD1 was shown to counteract Ab42
oligomer-induced apoptosis in HNG cells using MTT, Hoechst
33258 staining, TUNEL and assay of caspase-3 activity
(Figure 3A–G). These assays showed that over 48 h Ab42
oligomer triggers about 50% cell death with concomitant nuclear
compaction and striking apoptotic changes (Figure 3). Ab42
peptides also enhanced caspase-3 activity at least 6-fold, an effect
that was reduced in the presence of NPD1. Co-incubation of
50 nM NPD1 with Ab42 oligomer resulted in enhanced cell
viability and attenuation of Ab42 peptide-mediated apoptosis and
cytotoxicity (Figure 3).
NPD1 down-regulates Ab42 oligomer-induced pro-
inflammatory gene expression
Our previous DNA microarray-based analysis suggested anti-
inflammatory bioactivity of NPD1 in HNG cells, as shown by their
attenuation of Ab42 peptide-induced elevation of the pro-
inflammatory genes COX-2, TNF-a and B94 [9]. Here we
extended these studies by exploring NPD1 actions at both the
mRNA and protein levels using RT-PCR, Western assay, ELISA
Figure 4. NPD1 down-regulates Ab42-induced expression of
pro-inflammatory genes COX-2, TNFa and B94 at both the
mRNA (RT-PCR) and protein (Western blot or ELISA) level. HNG
cells were incubated with 5 mMo fA b42 oligomer in the absence or
presence of NPD1 (50 nM) for 3, 6 and 12 h. NPD1 suppressed Ab42
peptide-induced mRNA expression of COX-2, TNFa and B94. (A–C)
mRNA expression was detected by RT-PCR followed by agarose gel
electrophoresis (see Figure 4); (D,E) NPD1 reduced COX-2 and TNFa
protein abundance in response to Ab42 stress; (E) Time course of TNFa
secretion as detected by ELISA (n=3); (F,G) NPD1 reduced the number
of COX-2 and B94 positive cells after Ab42 peptide-induced stress. In F
and G HNG cells were incubated for 24 h under the indicated
treatments. Results are means 6 SEM. *p,0.01 vs. control; **p,0.01
vs. Ab42 peptide-treated.
doi:10.1371/journal.pone.0015816.g004
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basal abundance of TNF-a mRNA was low, B94 mRNA increased
during incubation at 6 h, and constitutive expression of COX-2
mRNA occurred during incubation. Ab42 increased mRNA
abundance of COX-2, TNF-a and B94 at 3, 6 and 12 h
(Figure 4A,B). COX-2 mRNA stood out because it displayed
immediate early-inducible gene behavior upon Ab42 peptide
exposure [9]. Protein expression of cellular COX-2, TNF-a
secreted to the incubation media, and immunocytochemistry of
COX-2 and B94 showed Ab42-stimulated enhancement and
NPD1 (50 nM) markedly reduced Ab42 oligomer-stimulated
mRNA increases as well as COX-2, TNF-a and B94 protein
expression (Figure 4C). NPD1 therefore elicits potent down-
regulation in the expression of a specific set of pro-inflammatory
and pro-apoptotic genes known to be up-regulated in AD hippo-
campus and in stressed HNG cell models of AD [9,41,43–46].
Messenger RNA, Western, ELISA and immunohistochemisty data
are presented in Figures 4 and 5.
NPD1 represses amyloidogenic processing of bAPP with
concomitant stimulation of non-amyloidogenic
processing
Ab42-peptides are secreted from human brain cells as they age or
in response to physiological stress [4,9,27,47,48]. The processing of
bAPP holoenzyme and secretion of bAPP fragments is controlled in
large part by alpha-, beta- and gamma- (a-,b-a n dc-) secretases
[3,4]. To assess the effects of NPD1 on secretase-mediated Ab42
peptide generation, we used HNG cells transiently-transfected with
bAPPsw and assayed for the abundance of the a-secretase–
generating enzymes precursor-ADAM10 (pro-ADAM10), mature-
ADAM10(m-ADAM10),b-amyloidcleavage enzyme (BACE1) and
the gamma-secretase presenilin-1 (PS1) (Figure 6). Western blot
analysis revealed that the steady-level of BACE1 was reduced by
500 nM of NPD1. Meanwhile, the active and mature form of
ADAM10 (m-ADAM10), the putative a-secretase, was dose-
dependently increased in response to NPD1. We did not find
changes in the pro-ADAM10, the inactive precursor or in the
Figure 5. HNG cells transfected with bAPPsw and treated with NPD1 - effects on precursor a-secretase (pro-ADAM10), mature
ADAM10 (m-ADAM10), b-secretase (BACE1) and c-secretase (PS1). (A) Control or HNG cells over-expressing bAPPsw were incubated with
increasing doses (0, 50, 100 and 500 nM, respectively) of NPD1 before cell lysates were harvested and subjected to Western blotting for the precursor
of ADAM10 (pro-ADAM10), mature ADAM10 (m-ADAM10), BACE1 and PS1 using the levels of b-actin as a control in the same sample; (B) Quantitation
of gel bands in (A); NPD1 activates m-ADAM10 while inhibiting BACE1 expression; quantification of m-ADAM10 and BACE1 expression by Western
blotting analysis after normalization to b-actin; results are means 6 SEM (n=3); *p,0.01 vs. bAPPsw control.
doi:10.1371/journal.pone.0015816.g005
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undergoing changes in these two secretases are in agreement with
alterations in Ab42 peptide abundance, and in other cleavage
products of bAPP (Figure 7). Interestingly, both m-ADAM10 and
BACE1 levels were elevated in bAPP-over-expressing cells
(Figure 6). Presenilin 1 (PS1), the main catalytic component for
c-secretase, remains unchanged after different bAPPsw or NPD1
treatments (Figure 6). This same pattern was also seen in their C-
terminal counterparts, CTFb and CTFa; importantly, no change
was observed in the steady-state level of the neural cell abundant
bAPP (holo-bAPP; see Figure 7A). NPD1-mediated up-regulation
of m-ADAM-10 and down-regulation of BACE1 was apparent with
maximal effect at 500 nM, the highest concentration used in these
experiments (Figures 6 and 7).
Quantification of bAPP Fragments
As Ab42 peptide generation is regulated by differential bAPP
processing, NPD1-mediated Ab42 peptide reduction is due to
altered bAPP processing, and thereby altered bAPP cleavage
products should confirm these catabolic outcomes. To test this
idea, we used HNG cells over-expressing bAPPsw, and measured
levels of N-terminal (sAPPa and sAPPbsw) and C-terminal
fragments (CTFa and CTFb)o fbAPP as well as holo-bAPP
protein upon exposure to increasing concentrations of NPD1. We
show that NPD1 lowers sAPPbsw secretion and elevates sAPPa in a
dose-dependent manner (Figure 7). This observation is paralleled
by a decrease in CTFb and an increase in CTFa in the same
cellular fractions and a significant 3.4-fold increase in mADAM10
(Figure 7).
Figure 6. NPD1 shifts bAPP processing from the amyloidogenic to the non-amyloidogenic pathway. (A) Control or HNG cells over-
expressing bAPPsw were treated with increasing concentrations (0, 50, 100, 500 nM) of NPD1 for 48 h and subjected to Western blot detection of
holo-bAPP (bAPP holoenzyme), sAPPa, sAPPbsw, CTFa and CTFb in comparison to b-actin levels in the same sample; (B) Quantification of gel bands in
(A) analyzing bAPP fragments with increasing doses of NPD1. Results are means 6 SEM (n=4); *p,0.01 vs. bAPPsw control.
doi:10.1371/journal.pone.0015816.g006
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BACE1
Collectively, these data suggests the participation and modula-
tion of BACE1 and ADAM10 activities in NPD1-mediated
regulation of bAPP processing. Just like ADAM10, ADAM9 is
also endowed with a-secretase activity [6,49], and changes in
BACE1 abundance may also contribute to Ab42 peptide
reduction. We therefore investigated whether ADAM 9, ADAM10
and BACE1 are essential to NPD1’s regulation of bAPP processing
by knocking down siRNA-targeted ADAM9 and ADAM10 genes.
We also over-expressed BACE1 by transfecting HNG cells with a
plasmid bearing the human BACE1 full length cDNA. We then
measured total bAPP and other bAPP cleavage fragments in the
presence of NPD1 with or without ADAM 9 siRNA or ADAM10
siRNA knockdown or BACE1 over-expression. As seen in
Figure 8, when compared to controls (control siRNA) no changes
occurred in ADAM9 siRNA group while ADAM10 siRNA-
mediated knockdown almost completely abrogated the induction
of sAPPa and CTFa by NPD1. Similarly, moderate over-
expression of BACE1 overturned NPD1-induced reduction in
Ab42 peptides along with sAPPbsw and CTFb fragments. These
results in combination with those shown in Figures 6 and 7
strongly suggests that NPD1’s regulatory action targeting bAPP
processing may be mediated in part through coordinated up-
regulation of the a-secretase ADAM10 and down-regulation of
BACE1 enzymatic activity.
NPD1 is a PPARc activator
PPARc is a key anti-inflammatory and Ab-lowering mediator,
and several polyunsaturated fatty acids and their derivatives are
ligands for PPARc. Thus, we asked whether NPD1 influences
PPARc actions, and if this could be related to its neuroprotective
bioactivity. We first tested NPD1 as a potential PPARc activator
using primary human adipocyte differentiation. PPARc is an
adipogenesis modulator, and PPARc agonists induce adipocyte
differentiation. Adipogenesis assay was used for screening potential
PPARc-active compounds. Primary human pre-adipocytes were
treated with 0.1, 1 and 5 mM of NPD1 or DHA during
differentiation induction (see Figure 9). Ligand-induced differen-
tiation was assessed by Oil Red O staining. NPD1 led to
enhancement of differentiation in the primary human pre-
adipocytes, while equivalent doses of its precursor DHA displayed
little adipogenic activity, suggesting that NPD1 does display
PPARc activity (Figure 9 and Figure S2). To further evaluate the
activity of NPD1, we used a cell-based PPARc transactivation
reporter assay. HNG cells co-transfected with hPPARc-GAL4 and
MH100-tk-luc were incubated with increasing concentrations (0.1,
1.0, 5.0 and 10 mM) of NPD1 or DHA for 24 h. NPD1, but not its
precursor DHA, increased reporter activity in a dose-dependent
manner indicating that NPD1 acts as an activator of an inducible
PPARc response (Figure 10A).
The anti-amyloidogenic effect of NPD1 is PPARc-
dependent
We further examined whether PPARc is involved in the
regulation by NPD1 of bAPP processing. First, we studied the
effect of PPARc on Ab42 peptide production in HNG cells over-
expressing bAPPsw by either transiently-transfecting PPARc
cDNA or using the PPARc agonist, rosiglitazone. The efficiency
of transfection and subcellular localization of both proteins were
monitored by immunofluorescence and Western blotting. The
majority of PPARc expression was found to be associated with the
HNG cell nuclei (Figure 10B,C). In both PPARc-transfected and
Figure 7. BACE1 and ADAM10 are required in NPD1-regulated
bAPP processing into the release of soluble Ab peptides and
Ab42 peptides (ng/ml cell culture medium). (A) Effects of control
siRNA, ADAM9 siRNA or ADAM10 siRNA on shedding of total Ab
peptides or Ab42 peptides into the HNG cell growth medium. (B) HNG
cells over-expressing bAPPsw were co-transfected with control siRNA or
siRNA specifically targeting ADAM9 or ADAM10, or with BACE1 plasmid
DNA for 48 h in the presence of 500 nM of NPD1. (C) Quantification of
gel bands in (B) analyzing bAPP fragments with increasing doses of
NPD1. Results are means 6 SEM (N=4); *p,0.01 vs. bAPPsw control.
Effects of different treatments are measured by ELISA for total Ab
peptides or Ab42 peptides (n=5), or by Western blotting (n=3);
* p,0.01 vs. bAPPsw control.
doi:10.1371/journal.pone.0015816.g007
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amount of secreted total Ab and Ab42. The decrease was
comparable to that conferred by NPD1 treatment. To determine
whether PPARc is required in this action, HNG cells were also
incubated with the PPARc antagonist, GW9662. GW9662
reversed the Ab peptide reduction in NPD1-treated cells and in
PPARc over-expression or PPARc agonist-treated cells as well
(Figure 11A). These results suggest that PPARc is required for
NPD1’s regulation of Ab release. To further define the action of
PPARc on bAPP processing and its implication in the anti-
amyloidogenic effect of NPD1, we analyzed the levels of bAPP
fragments using the above treatments. Similar to NPD1-induced
reduction in sAPPb and CTFb, in cells over-expressing PPARc or
treated with PPARc agonist, these two b-secretase cleavage
products were substantially down-regulated (Figure 11B,D,E).
Just as in the case of Ab peptide release, this down-regulatory
effect was reversed by the addition of PPARc antagonist in all
relevant treatment groups (Figure 11B,D,E). Note that GW9662
alone caused no changes in either sAPPbsw or CTFb
(Figure 11C). In contrast, unlike NPD1, PPARc overexpression
or PPARc agonist did not modify the levels of sAPPa or CTFa.
Nor did the PPARc antagonist abolish the NPD1-induced increase
in these fragments (Figure 11B,D,E). Meanwhile, no changes in
holo-bAPP by PPARc were observed (Figure 11B). These data
suggest that PPARc is involved in NPD1’s regulation via the b-
secretase pathway but not via the a-secretase pathway. We next
examined the levels of ADAM10 and BACE1, the putative a- and
b-secretase that are actively involved in NPD1’s modulation of
Figure 8. Human pre-adipocytes were cultured according to the manufacturer’s instructions (Zen-Bio, Research Triangle Park, NC)
(A). Upon initiation of the differentiation assay, pre-adipocytes were incubated in adipocyte medium supplemented with vehicle (control), NPD1 or
DHA (see Materials and Methods). Results quantified in bar graph format indicate significant up-regulation of lipid accumulation in NPD1-treated, in
contrast to DHA-treated, human pre-adipocyte cells (B).
doi:10.1371/journal.pone.0015816.g008
Neuroprotectin D1 Induces Neural Cell Survival
PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e15816APP processing. In agreement with the alterations in levels of
bAPP fragments, PPARc activation reduced the steady-state level
of BACE1 expression but did not affect ADAM10. PPARc
antagonism abolished the NPD1-induced decrease in BACE1 but
was not able to reverse the increase in mature ADAM10 level
(Figure 11B,F).
Discussion
DHA partially counteracts cognitive decline in the elderly [11].
Moreover, omega-3 essential fatty acid-rich diets are associated
with a trend in reduced risk for MCI and with MCI conversion to
AD, whereas DHA has been shown to be beneficial in transgenic
AD models [8,10,11,16,50]. The 15-lipoxygenase-1- (15-LOX-1)
DHA-derived NPD1 displays neuroprotective bioactivity in brain
and retinal cells against various insults, including oxidative injury,
ischemia-reperfusion and inflammation [9,17,18,51–53]. Both AD
brain [9] and the 3xTg-AD mouse exhibit reductions in DHA and
NPD1 (Figure 1). In this study we further characterized the anti-
inflammatory and anti-apoptotic activity of NPD1 in co-cultures of
HNG cells stressed with Ab42 oligomer, and studied the NPD1-
mediated modulation of a- and b-secretase activity that resulted in
reduced shedding of Ab42.
AD is marked by synaptic damage, neuronal atrophy and cell
death in the hippocampus and entorhinal cortex [4,54–56].
Neurotoxicity induced by Ab42 aggregates appears to drive
microglial-mediated neuroinflammatory responses and apoptosis
[3,4,50,57]. Oxidative stress, calcium overload, mitochondrial
dysfunction and membrane impairments, along with activation of
caspases and cell death are associated with Ab42 up-regulation
[55]. We found that NPD1 induces HNG cell survival after Ab42-
oligomer-mediated stress and reduced Ab42-triggered apoptosis.
NPD1 attenuated caspase-3 activation and decreased compacted
nuclei and fragmented DNA [18,19] (Figure 3). These observa-
tions are in agreement with the NPD1-mediated up-regulation of
anti-apoptotic Bcl-2, Bcl-xl and Bfl-1 expression and the decrease
in the pro-apoptotic expression of Bax, Bad and Bik [9,18].
Neuroinflammatory neurodegeneration associated with Ab42 is
an important contributory event to AD neuropathology [54,56].
In these experiments primary HNG cells were used, as human
primary neurons do not survive well in the absence of glial cells
[9,29] (Figure 2). While we cannot exclude the possibility that
glial cells are providing some neuroprotective ‘shielding’, both
neuronal and glial cells release cytokines when exposed to Ab42
that, in turn, activate more microglia and astrocytes that reinforce
pathogenic signaling. NPD1 is anti-inflammatory and promotes
inflammatory resolution [17,18,37,53]. In HNG cell models of
Ab42 toxicity, microarray analysis and Western blot analysis
revealed down-regulation of pro-inflammatory genes (COX-2,
TNF-a and B94), suggesting NPD1’s anti-inflammatory bioactivity
targets, in part, this gene family [9]. These effects are persistent, as
shown by time-course Western blot analysis in which protein
expression was examined up to 12 h after treatment by Ab42 and
NPD1.
Although counteracting Ab42-induced neurotoxicity is a
promising strategy for AD treatment, curbing excessive Ab42
release during neurodegeneration is also desirable. DHA could
lower Ab42 load in the CNS by stimulating non-amyloidogenic
bAPP processing, reducing PS1 expression, or by increasing the
expression of the sortilin receptor, SorLA/LR11 [8,21,41,58]. In
contrast to a previous report by Green et al. [16] that suggested
that Ab peptide reductions in whole brain homogenates of 3xTg
AD after dietary supplementation of DHA were the result of
decreases in the steady state levels of PS1, our experiments in
primary HNG cells showed no effects of NPD1 on PS1 levels, but
a significant increase in ADAM10 coupled to a decrease in
BACE1 (Figure 5). These later observations were further
confirmed by both activity assays (Figures 6 and 7) and siRNA
knockdown (Figure 8). NPD1 reduces Ab42 levels released from
HNG cells over-expressing APPsw in a dose-dependent manner.
Our examination of other bAPP fragments revealed after NPD1
Figure 9. NPD1 activates PPARc. (A) PPARc activities upon
incubation with NPD1 or DHA are shown in bar graph format. The
activation of PPARc by NPD1 and DHA was assessed using a cell-based
luciferase reporter transactivation assay after incubation with increasing
concentrations (0.1, 1.0, 5.0 and 10.0 mM) of NPD1 or DHA for 24 h.
Luciferase activity was normalized to b-gal activity (transfection
efficiency control) and results were expressed as fold-change of
induction relative to vehicle treated HNG cells (n=4). Horizontal
dashed line at 1.0 indicates control PPARc levels at 1 mM for ease of
comparison; *p,0.01 vs. corresponding vehicle controls. (B) Co-
transfection of bAPPsw and PPARc in HNG cells; immunofluorescence
detection of bAPPsw (green; l=530 nm) and PPARc (red; l=670 nm) in
HNG cells over-expressing both proteins; HNG nuclei are stained with
DAPI (blue; l=470 nm); overlap of PPARc and HNG cell nuclear signal
(violet; l=420 nm; arrows) indicates nuclear association of PPARc; 40x
magnification. (C) Two-color Western blot with Odyssey infrared
imaging showing over-expression of both bAPPsw (green) and PPARc
(red) in whole HNG cell extracts.
doi:10.1371/journal.pone.0015816.g009
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CTFb occurred, along with an increase in a-secretase products
sAPPa and CTFa, while levels of bAPP expression remained
unchanged in response to NPD1. Hence these abundance- and
activity-based assays indicate a shift by NPD1 in bAPP processing
from the amyloidogenic to non-amyloidogenic pathway. Previ-
ously sAPPa has been found to promote NPD1 biosynthesis from
DHA [9], while in the present study NPD1 works to stimulate
sAPPa secretion, creating positive feedback and neurotrophic
reinforcement. Secreted sAPPa’s beneficial effects include en-
hanced learning, memory and neurotrophic properties [6]. NPD1
further down-regulated the b-secretase BACE1 and activated
ADAM10, a putative a-secretase. Our ADAM10 siRNA knock-
down and BACE1 over-expression-activity experiments confirmed
that ADAM10 and BACE1 are required in NPD1’s regulation of
bAPP. NPD1 therefore appears to function favorably in both of
these competing bAPP processing events.
PPARc activation leads to anti-inflammatory, anti-amyloido-
genic actions and anti-apoptotic bioactivity, as does NPD1. Some
fatty acids are natural ligands for PPARc, which have a
predilection for binding polyunsaturated fatty acids [59–61].
Our hypothesis that NPD1 is a PPARc activator was confirmed
by results from both human adipogenesis and cell-based-
transactivation assay (Figures 9 and 10). NPD1 may activate
PPARc via direct binding or other interactive mechanisms
[33,62]. Analysis of bAPP-derived fragments revealed that PPARc
does play a role in the NPD1-mediated suppression of Ab
production. Over-expressing PPARc or incubation with a PPARc
agonist led to reductions in Ab, sAPPb and CTFb similar to that
with NPD1 treatment, while a PPARc antagonist abrogated these
reductions. Activation of PPARc signaling is further confirmed by
the observation that PPARc activity decreased BACE1 levels, and
a PPARc antagonist overturned this decrease. Thus, the anti-
amyloidogenic bioactivity of NPD1 is associated with activation of
the PPARc and the subsequent BACE1 down-regulation. The
difference between the bioactivity of NPD1 concentrations for
anti-apoptotic and anti-amyloidogenic activities (50 nM vs.
500 nM) may be due to the different cell models used (i.e., Ab-
peptide stressed vs. bAPPsw-over-expressing HNG cells) and/or
related mechanisms.
Although Ab-lowering effects of PPARc have been reported,
the molecular mechanism of this action remains unclear.
Induction of bAPP ubiquitination, which leads to enhanced bAPP
degradation and reduced Ab peptide secretion, has been suggested
[60]. Alternatively, Ab clearance might be involved, or regulation
by PPARc may be due to enhancement of insulin sensitivity and
increases in brain insulin degrading enzyme [59]. Our results
suggest that decreases in BACE1 may be the cause for Ab
reduction [27,63]. A reason for these conflicting reports may be
that cell models and culture conditions used varied; in our study,
we used HNG cells transiently over-expressing bAPPsw while
previous reports employed cell lines using stable bAPP expression.
Figure 10. PPARc activation is required for anti-amyloidogenic effect of NPD1 but not for activation of ADAM10. HNG cells over-
expressing bAPPsw were co-transfected with 2.0 mg of pEGFP or PPARc cDNA or incubated with 0.5 mM of NPD1 or rosiglitazone (RGZ) in the absence
or presence of 2 mM of GW9662 for 48 h before being harvested for assay. (A) ELISA assay of total Ab and Ab42 peptides (ng/ml) from conditioned
media of HNG cells with different treatments; (B) Western blot analysis of bAPP fragments as well as ADAM10 and BACE1 from HNG cells under
different conditions as indicated in the lower part of panel (B) in these Western images; (C) Western analysis of sAPPbsw or CTFs from HNG cells over-
expressing bAPPsw in the absence or presence of 2 mM of GW9662; (D–F) Quantification of bAPP fragments, ADAM10 and BACE1 levels based on
Western results (n=3). *p,0.01 vs. bAPPsw control; **p,0.01 vs bAPPsw + pEGFP co-transfection; *N p,0.01 vs. bAPPsw + NPD1; *R p,0.01 vs. bAPPsw
+ rosiglitazone; **p,0.01 vs. bAPPsw + PPARc co-transfection.
doi:10.1371/journal.pone.0015816.g010
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increases in ab overproduction. Excessive Ab causes inflammatory
responses in both neuronal and glial cells [27]. Since inflammatory
signaling plays a role in AD pathogenesis, we believe HNG cell
cultures are a valuable model for Ab42 -mediated cellular actions.
The fact that comparable results of our study were obtained at a
much lower drug concentration (0.5 mM of rosiglitazone vs. 10–
30 mM in previous reports) (Figure 10) underscores the highly
sensitive nature of HNG cells after bAPP transfection. It is still
possible that PPARc may repress BACE1 by antagonizing
activities of other transcription factors that promote BACE1
expression, such as STAT1, NF-kB and AP1 [64]. It is noteworthy
that BACE1 expression in HNG cells was increased after bAPP
over-expression. The fact that PPARc did not affect the levels of
sAPPa and CTFa besides PPARc antagonist being unable to
reverse NPD1-elicited increase in these fragments, clearly show
that PPARc is not essential for NPD1’s regulation on the non-
amyloidogenic pathway. Further analysis of ADAM10 showed no
change occurring in ADAM10 following PPARc activation, nor
did PPARc antagonists affect NPD1-enhanced expression of
mature ADAM10. Therefore, modulation by NPD1 of a-secretase
and bAPP processing are independent of PPARc. ADAM10 is
synthesized as an inactive zymogene and is processed to its mature
form by cleavage of the pro-domain by pro-protein convertases
(PPCs), such as furin and PC7 [65]. Other evidence also
demonstrated that protein kinase C (PKC) and mitogen-activated
protein (MAP) kinase, particularly extracellular signal-regulated
kinases (ERK1/2), are involved in regulation of a-secretase activity
[62,66,67]. No cross-talk between the PCs and PKC or MAP
kinases has been reported. Since in our study only the mature
ADAM10 was increased, it is likely that the PPCs are implicated in
NPD1 actions.
PPARc antagonist GW9662 also failed to reverse the anti-
apoptotic effect of NPD1, indicating that PPARc is not implicated
in NPD1 anti-apoptotic bioactivity (Figure 10). NPD1 attained
this neuroprotection at a concentration of 50 nM, at which its
PPARc activity is far from physiologically relevant in the in vitro
system. Other mechanisms have been proposed to explain DHA’s
anti-apoptotic and anti-inflammatory effects, including mainte-
nance of plasma membrane integrity, activation of Akt signaling
[68], and conversion into other derivatives [23,50]. These findings
also provide clues for NPD1’s potential targets. NPD1 inhibits NF-
kB activation and COX-2 expression in brain ischemia-reperfu-
sion [17], while Ab peptide-induced apoptosis is associated with
ERK and p38 MAPK-NF-kB mediated COX-2 up-regulation
[44]. Neuroprotection mediated by NPD1 may further involve
components of signaling pathways upstream of NF-kB activation
and DNA-binding [9].
Our results provide compelling evidence that NPD1 is endowed
with strong anti-inflammatory, anti-amyloidogenic, and anti-
apoptotic bioactivities in HNG cells upon exposure to Ab42
oligomers, or in HNG cells over-expressing bAPPsw. These results
suggest that NPD1’s anti-amyloidogenic effects are mediated in
part through activation of the PPARc receptor, while NPD1’s
stimulation of non-amyloidogenic pathways is PPARc-indepen-
dent. Suggested sites of NPD1 actions are schematically presented
in Figure 11. NPD1 stimulation of ADAM10 coupled to
suppression of BACE1-mediated Ab42 secretion clearly warrants
further study, as these dual secretase-mediated pathways may
provide effective combinatorial or multi-target approaches in the
clinical management of the AD process.
Supporting Information
Figure S1 Characterization of Ab peptide preparations
using LMW-Western analysis. (A) Lanes 1 and 2 represent
duplicate Ab peptide preparations prepared and analyzed by one
of the authors (WJL), and (B)A b peptide preparations prepared
and analyzed completely independently by another one of the
authors (YZ); both Ab peptide preparations were prepared and
Figure 11. NPD1 promotes non-amyloidogenic, neurotrophic bioactivity via pleiotrophic mechanisms. Membrane esterified DHA is
excised by phospholipase A2 (PLA2) to yield free DHA; in turn free DHA is 15-lipoxygenated to generate NPD1 which then enters a neuroprotective
cycle. These events are mediated, in part, by inhibiting apoptosis, by blocking inflammatory signaling, by promoting cell survival and by shifting bAPP
processing from an amyloidogenic into a neurotrophic, non-amyloidogenic pathway. BACE1 activity is suppressed and a-secretase (ADAM10) activity
is stimulated, thus down-regulating Ab42 peptide release from membranes. Augmentation of BACE1 and ADAM10 by NPD1 may be mediated via
other neuromolecular factors. We note that the ADAM10 cleavage product sAPPa further induces the conversion of free DHA into NPD1, thus
constituting a positive, neurotrophic feedback loop.
doi:10.1371/journal.pone.0015816.g011
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1,1,1,3,3,3-hexafluoro-2-propanol) preparative and gel analytical
methods described by Stine et al., (J Biol Chem. 278:11612-
22,2003). No higher order Ab fibrils are evident in either (A)o r
(B). Panel (C) shows relative toxicity of monomer, fibril and
oligomer preps shown in (B) as analyzed using MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium; Invitrogen] cell vi-
ability assay.
(TIF)
Figure S2 Dose response of vehicle (control), NPD1 and
DHA (at 0.1, 0.5, 1.0, 5.0 and 10.0 mM) on PPARc activity
- effects on PPARc activity using luciferase reporter fold
change over controls. Experimental conditions are further
described in the text.
(TIF)
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